Inhibition of the transcription factor C/EBPβ causes both tumor cell death and macrophage repolarization, a unique combination of cytotoxic and immune-activating functions.
C/EBPβ – a Development Stage Transcription Factor that Drives the Expression of:
- Survivin (BIRC5), cIAP2 (BIRC3), Bcl family proteins: survival
- Cyclins: proliferation
- ID proteins: tumorigenesis
- CD206, CD209: M2 macrophage polarization
- IL-6: immune suppression
ST101 MOA
Tumor
Tumor Microenvironment
Ongoing ST101 Phase 1-2 Clinical Trial
ST101 is currently in the Phase 2 portion of an ongoing Phase 1-2 monotherapy study in patients with recurrent GBM (rGBM). In a “window of opportunity” surgical sub-study of the ST101 trial, ST101 is being evaluated as a monotherapy in rGBM and in combination with radiation and temozolomide in newly diagnosed GBM (ndGBM).